Based on the earnings transcript, Amgen shows strong positive indicators for short-term stock performance:

1. Strong Q4 and full-year 2012 performance with 9% product sales growth for the full year and 11% for Q4
2. Solid 2013 guidance projecting 3-5% revenue growth and 5-10% EPS growth
3. Early achievement of 2015 targets, with management indicating they'll hit the upper end of revenue guidance two years early
4. Significant shareholder returns through increased dividends (31% increase) and continued share buybacks
5. Stable market leadership positions in key products and successful strategic acquisitions

The company demonstrates strong execution, good cash flow generation, and confident management guidance, suggesting positive momentum for the stock in the near term.

[1]